In yesterday’s Wall Street session, Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) shares traded at $7.00, down -1.69% from the previous session.
As of this writing, 8 analysts cover Phathom Pharmaceuticals Inc. (NASDAQ:PHAT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $9.00, we find $21.00. Given the previous closing price of $7.12, this indicates a potential upside of 194.94 percent. PHAT stock price is now -25.35% away from the 50-day moving average and -26.07% away from the 200-day moving average. The market capitalization of the company currently stands at $318.01M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
There are 2 analysts who have given it a hold rating, whereas 6 have given it a buy rating. Brokers who have rated the stock have averaged $19.43 as their price target over the next twelve months.
With the price target of $21, Craig Hallum recently initiated with Buy rating for Phathom Pharmaceuticals Inc. (NASDAQ: PHAT). On October 21, 2022, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $16, while ‘Evercore ISI’ rates the stock as ‘In-line’.
In other news, Henderson Molly, CFO and CBO sold 2,032 shares of the company’s stock on Mar 01. The stock was sold for $17,335 at an average price of $8.53. Upon completion of the transaction, the CFO and CBO now directly owns 76,015 shares in the company, valued at $0.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, President and Chief Executive Curran Terrie sold 1,436 shares of the business’s stock. A total of $12,265 was realized by selling the stock at an average price of $8.54. This leaves the insider owning 175,371 shares of the company worth $1.23 million. Insiders disposed of 9,506 shares of company stock worth roughly $66542.0 over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PHAT stock. A new stake in Phathom Pharmaceuticals Inc. shares was purchased by OPALEYE MANAGEMENT INC. during the first quarter worth $2,923,000. WALLEYE CAPITAL LLC invested $1,021,000 in shares of PHAT during the first quarter. In the first quarter, GSA CAPITAL PARTNERS LLP acquired a new stake in Phathom Pharmaceuticals Inc. valued at approximately $130,000. MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. acquired a new stake in PHAT for approximately $93,000. AQR CAPITAL MANAGEMENT LLC purchased a new stake in PHAT valued at around $70,000 in the second quarter. In total, there are 151 active investors with 76.00% ownership of the company’s stock.
Wednesday morning saw Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) opened at $6.99. During the past 12 months, Phathom Pharmaceuticals Inc. has had a low of $6.09 and a high of $16.07. The fifty day moving average price for PHAT is $9.29 and a two-hundred day moving average price translates $9.47 for the stock.
The latest earnings results from Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$1.32, inline with analysts’ expectations of -$1.32. This compares to -$0.95 EPS in the same period last year. The company reported revenue of $46.64 million for the quarter, compared to $33.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 41.17 percent.
Phathom Pharmaceuticals Inc.(PHAT) Company Profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Leave a Reply